A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

NCT07702578 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

310

Enrollment

INDUSTRY

Sponsor class

Conditions

AML
MDS

Interventions

DRUG: TSC-101
OTHER: Control

Sponsor

TScan Therapeutics, Inc.